# EDGAR Filing Document

**Accession Number:** 0001541157
**File Stem:** 0001493152-26-008874
**Filing Date:** 2026-3
**Character Count:** 8765
**Document Hash:** d610324ae08a0c692dbd87a43ddd3d40
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-008874.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001493152-26-008874

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981034922
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87614
- **FILM NUMBER:** 26722233

**BUSINESS ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602
- **BUSINESS PHONE:** (929) 274-7510

**MAIL ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Patel Samir Rashmikant
- **CENTRAL INDEX KEY:** 0001702447

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 1111 MAIN STREET
- **STREET 2:** SUITE 660
- **CITY:** VANCOUVER
- **STATE:** WA
- **ZIP:** 98660

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Akari Therapeutics Plc**

*(Name of Issuer)*

**Ordinary Shares, $0.000000005 par value**

*(Title of Class of Securities)*

**00972G207**

*(CUSIP Number)*

**Win Rutherfurd, Esq.**<br>Greenberg Traurig, LLP<br>One Vanderbilt Avenue<br>New York NY 10017<br>(212) 801-9200

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/02/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **00972G207** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samir R. Patel** | Name of reporting person<br>**Samir R. Patel** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**9725215000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**9725215000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9725215000.00** | Aggregate amount beneficially owned by each reporting person<br>**9725215000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.4%** | Percent of class represented by amount in Row (11)<br>**10.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares.
2) Includes (i) 285,336,000 shares held of record by Dr. Patel, (ii) 6,062,010,000 shares held of record by PranaBio Investments LLC ("PranaBio"), (iii) 1,579,785,000 options exercisable within 60 days of March 1, 2026 granted to Dr. Patel and (iv) 1,798,084,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026 to PranaBio. Excludes up to (ii) 5,450,454,000 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Dr. Patel which are subject to a 9.99% beneficial ownership limitation and with respect to which Dr. Patel disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. Dr. Patel is the manager of PranaBio and may be deemed the beneficial owner of the shares held of record by PranaBio.
3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, $0.000000005 par value

**(b) Name of Issuer:**
Akari Therapeutics Plc

**(c) Address of Issuer's Principal Executive Offices:**
401 East Jackson Street, Suite 3300, Tampa, FL, 33602

This Amendment No. 2 to Schedule 13D ("Amendment No. 2") amends and supplements where indicated the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on June 7, 2024 and amended on December 6, 2024, (collectively, the "Prior Schedule 13D") by and on behalf PranaBio Investments LLC ("PranaBio") and Samir R. Patel  (collectively, the "Reporting Person"), and relates to the ordinary shares, $0.000000005 par value ("Ordinary Shares") of Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the "Issuer"). The Issuer's American Depositary Shares, each representing 2,000 Ordinary Shares (the "ADSs"), have been registered on a registration statement on Form F-6 (File No. 333-185197), as supplemented (File Nos. 333-234213, 333-262049 and 333-185197), and trade on the Nasdaq Capital Market under the symbol "AKTX." Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Prior Schedule 13D. This Amendment No. 2 amends and supplements the Prior Schedule 13D as specifically set forth herein. Except as set forth below, all previous Items in the Prior Schedule 13D remain unchanged. This Amendment No. 2 is being filed to amend Items 3, 4 and 5 as set forth below and to update the number of shares of Ordinary Shares beneficially held by the Reporting Persons as a result of the transaction described below.

**Item 4. Purpose of Transaction**

On December 17, 2025, Dr. Patel purchased the securities described in the transactions as described in Item 3 above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person, either in his individual capacity or as sole manager and member of PranaBio Investments LLC, beneficially owns an aggregate of (i) 285,336,000 shares held of record by Dr. Patel, (ii) 6,062,010,000 shares held of record by PranaBio (iii) 1,579,785,000 options exercisable within 60 days of March 1, 2026 granted to Dr. Patel and (iv) 1,798,084,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026 to PranaBio. Excludes up to (ii) 5,450,454,000 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Dr. Patel which are subject to a 9.99% beneficial ownership limitation and with respect to which Dr. Patel disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. Dr. Patel is the manager of PranaBio and may be deemed the beneficial owner of the shares held of record by PranaBio.

**(b)**
See Rows 7 through 11 of cover page for Reporting Persons.

**(c)**
None of the Reporting Persons has effected any transactions in Ordinary Shares during the 60 days prior to the filing of this Amendment No. 2.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samir R. Patel

**Signature:** /s/ Samir R. Patel

**Name/Title:** Samir R. Patel, Authorized Signatory

**Date:** 03/04/2026